Literature DB >> 12383572

Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.

Marco Metra1, Savina Nodari, Antonio D'Aloia, Claudio Muneretto, Alastair D Robertson, Michael R Bristow, Livio Dei Cas.   

Abstract

OBJECTIVE: We compared the hemodynamic effects of dobutamine and enoximone administration before and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with chronic heart failure (HF).
BACKGROUND: Patients with HF on beta-blocker therapy may need hemodynamic support with inotropic agents, and the hemodynamic response may be influenced by both the inotropic agent and the beta-blocker used.
METHODS: The hemodynamic effects of dobutamine (5 to 20 microg/kg/min intravenously) and enoximone (0.5 to 2 mg/kg intravenously) were assessed by pulmonary artery catheterization in 29 patients with chronic HF before and after 9 to 12 months of treatment with metoprolol or carvedilol at standard target maintenance oral doses. Hemodynamic studies were performed after >/=12 h of wash-out from all cardiovascular medications, except the beta-blockers that were administered 3 h before the second study.
RESULTS: Compared with before beta-blocker therapy, metoprolol treatment decreased the magnitude of mean pulmonary artery pressure (PAP) and pulmonary wedge pressure (PWP) decline during dobutamine infusion and increased the cardiac index (CI) and stroke volume index (SVI) response to enoximone administration, without any effect on other hemodynamic parameters. Carvedilol treatment abolished the increase in heart rate, SVI, and CI and caused a rise, rather than a decline, in PAP, PWP, systemic vascular resistance, and pulmonary vascular resistance during dobutamine infusion. The hemodynamic response to enoximone, however, was maintained or enhanced in the presence of carvedilol.
CONCLUSIONS: In contrast with its effects on enoximone, carvedilol and, to a lesser extent, metoprolol treatment may significantly inhibit the favorable hemodynamic response to dobutamine. No such beta-blocker-related attenuation of hemodynamic effects occurs with enoximone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12383572     DOI: 10.1016/s0735-1097(02)02134-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  48 in total

Review 1.  The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series).

Authors:  Michael R Bristow; Robert A Quaife
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 2.  Beta-blocker use in decompensated heart failure.

Authors:  Rami Alharethi; Ray E Hershberger
Journal:  Curr Heart Fail Rep       Date:  2006-06

Review 3.  Management of acute decompensated heart failure.

Authors:  Larry A Allen; Christopher M O'Connor
Journal:  CMAJ       Date:  2007-03-13       Impact factor: 8.262

4.  Altered responses to vasopressors of a patient medicated with carvedilol, pilsicainide and enalapril.

Authors:  Kumi Nakamura; Norihiko Fukami
Journal:  J Anesth       Date:  2013-12-24       Impact factor: 2.078

5.  Acute Heart Failure Treatment.

Authors:  Phillip D Levy; Abdel Bellou
Journal:  Curr Emerg Hosp Med Rep       Date:  2013-06-01

6.  Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adrenoreceptor activation.

Authors:  Oleg E Osadchii; Angela J Woodiwiss; Gavin R Norton
Journal:  Pflugers Arch       Date:  2005-12-17       Impact factor: 3.657

Review 7.  Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents.

Authors:  Marco Metra; Luca Bettari; Valentina Carubelli; Silvia Bugatti; Alessandra Dei Cas; Francesca Del Magro; Valentina Lazzarini; Carlo Lombardi; Livio Dei Cas
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

Review 8.  Pediatric heart failure therapy with beta-adrenoceptor antagonists.

Authors:  Susan R Foerster; Charles E Canter
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 9.  Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.

Authors:  John R Teerlink; Marco Metra; Valerio Zacà; Hani N Sabbah; Gadi Cotter; Mihai Gheorghiade; Livio Dei Cas
Journal:  Heart Fail Rev       Date:  2009-12       Impact factor: 4.214

10.  Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.

Authors:  Marco Metra; Eric Eichhorn; William T Abraham; Jennifer Linseman; Michael Böhm; Ramon Corbalan; David DeMets; Teresa De Marco; Uri Elkayam; Michael Gerber; Michel Komajda; Peter Liu; Vyacheslev Mareev; Sergio V Perrone; Philip Poole-Wilson; Ellen Roecker; Jennifer Stewart; Karl Swedberg; Michal Tendera; Brian Wiens; Michael R Bristow
Journal:  Eur Heart J       Date:  2009-12       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.